Shots: Xbrane reported that the last patient has been enrolled into the P-III XPLORE study assessing Xlucane vs Lucentis in 580 patients with wet AMD The company will conduct an interim read-out from the XPLORE study when the last patient has reached 6mos. of their treatment schedule. Top-line data is expected to be communicated mid-2021 […]Read More
Shots: The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the […]Read More
Shots: The multiple expansion cohort will assess the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors harboring a KRAS G12C mutation Strata Oncology will identify patients to be considered for enrollment into Mirati’s P-I/II study. The Strata Trial provides tumor molecular profiling for patients with advanced […]Read More
Shots: FibroGen initiates the P-II study assessing the efficacy and safety of pamrevlumab vs SOC in hospitalized patients in a ratio (1:1) with acute COVID-19 across the US and is expected to enroll ~130 patients The focus of the study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 with […]Read More
Shots: The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda, characterizing PK/PD profile and to determine the recommended dose of the combination regimen The study is divided into two parts into Part A, a dose escalation of BI-1206 in combination with the standard dose of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
